Literature DB >> 15681394

Pulmonary vascular effects of sildenafil on the development of chronic pulmonary hypertension in the ovine fetus.

B Larrue1, S Jaillard, M Lorthioir, X Roubliova, G Butrous, T Rakza, H Warembourg, L Storme.   

Abstract

We investigated the pulmonary vascular effects of prophylactic use of sildenafil, a specific phosphodiesterase-5 inhibitor, in late-gestation fetal lambs with chronic pulmonary hypertension. Fetal lambs were operated on at 129 +/- 1 days gestation (term = 147 days). Ductus arteriosus (DA) was compressed for 8 days to cause chronic pulmonary hypertension. Fetuses were treated with sildenafil (24 mg/day) or saline. Pulmonary vascular responses to increase in shear stress and in fetal PaO2 were studied at, respectively, day 4 and 6. Percent wall thickness of small pulmonary arteries (%WT) and the right ventricle-to-left ventricle plus septum ratio (RVH) were measured after completion of the study. In the control group, DA compression increased PA pressure (48 +/- 5 to 72 +/- 8 mmHg, P < 0.01) and pulmonary vascular resistance (PVR) (0.62 +/- 0.08 to 1.15 +/- 0.11 mmHg x ml(-1) x min(-1), P < 0.05). Similar increase in PAP was observed in the sildenafil group, but PVR did not change significantly (0.54 +/- 0.06 to 0.64 +/- 0.09 mmHg x ml(-1) x min(-1)). Acute DA compression, after brief decompression, elevated PVR 25% in controls and decreased PVR 35% in the sildenafil group. Increased fetal PaO2 did not change PVR in controls but decreased PVR 60% in the sildenafil group. %WT and RVH were not different between groups. Prophylactic sildenafil treatment prevents the rise in pulmonary vascular tone and altered vasoreactivity caused by DA compression in fetal lambs. These results support the hypothesis that elevated PDE5 activity is involved in the consequences of chronic pulmonary hypertension in the perinatal lung.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15681394     DOI: 10.1152/ajplung.00405.2004

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  6 in total

1.  The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.

Authors:  Ghazwan Butrous
Journal:  Glob Cardiol Sci Pract       Date:  2014-10-16

2.  Effects of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) on Fetal Pulmonary Circulation: An Experimental Study in Fetal Lambs.

Authors:  Dyuti Sharma; Estelle Aubry; Thavarak Ouk; Ali Houeijeh; Véronique Houfflin-Debarge; Rémi Besson; Philippe Deruelle; Laurent Storme
Journal:  Nutrients       Date:  2017-07-16       Impact factor: 5.717

3.  Case Report: Persistent Pulmonary Hypertension of the Newborn and Narrowing of the Ductus Arteriosus After Topical Use of Non-Steroidal Anti-Inflammatory During Pregnancy.

Authors:  Kévin Le Duc; Sixtine Gilliot; Jean Benoit Baudelet; Sébastien Mur; Mohamed Riadh Boukhris; Olivia Domanski; Pascal Odou; Laurent Storme
Journal:  Front Pharmacol       Date:  2021-11-25       Impact factor: 5.810

4.  Maternal consumption of polyphenol-rich foods in late pregnancy and fetal ductus arteriosus flow dynamics.

Authors:  P Zielinsky; A L Piccoli; J L Manica; L H Nicoloso; H Menezes; A Busato; M R Moraes; J Silva; L Bender; P Pizzato; L Aita; M Alievi; I Vian; L Almeida
Journal:  J Perinatol       Date:  2009-07-30       Impact factor: 2.521

5.  Decreased Cyclic Guanosine Monophosphate-Protein Kinase G Signaling Impairs Angiogenesis in a Lamb Model of Persistent Pulmonary Hypertension of the Newborn.

Authors:  Megha Sharma; Ujala Rana; Chintamani Joshi; Teresa Michalkiewicz; Adeleye Afolayan; Abdul Parchur; Amit Joshi; Ru-Jeng Teng; Girija G Konduri
Journal:  Am J Respir Cell Mol Biol       Date:  2021-11       Impact factor: 6.914

6.  Role of phosphodiesterase 5 in synaptic plasticity and memory.

Authors:  Daniela Puzzo; Salvatore Sapienza; Ottavio Arancio; Agostino Palmeri
Journal:  Neuropsychiatr Dis Treat       Date:  2008-04       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.